THE ROLE OF SILDENAFIL IN MODERATE TO SEVERE CF LUNG DISEASE

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这项研究是一项小型研究，旨在观察西地那非是否安全有效地减少囊性纤维化[CF]的炎症。 CF中的肺部疾病部分是由于细菌感染以及身体对抗感染的反应[称为炎症]。一些用于治疗CF肺病的药物旨在减少这种炎症。 实验室的研究人员已经表明，用西地那非治疗的CF细胞中的炎症和感染减少。 目前尚不清楚用西地那非治疗CF患者是否也会减少炎症和感染。 本研究的目的是确定用西地那非治疗CF患者是否能减少炎症。 我们还将测试它是否使CF患者感觉更好，并允许他们更多地锻炼。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This research is a small study being done to see if sildenafil is safe and effective in decreasing inflammation in cystic fibrosis [CF]. Lung disease in CF develops in part because of bacterial infection, and the body's response to fight the infection [called inflammation]. Some of the medications used to treat CF lung disease are aimed at decreasing this inflammation. Researchers in laboratories have shown that inflammation and infection are decreased in CF cells that are treated with sildenafil. It is not known if treating CF patients with sildenafil will also decrease inflammation and infection. The purpose of this study is to determine if treating CF patients with sildenafil decreases inflammation. We will also test whether it makes CF patients feel better and allows them to exercise more.